Startup | August 13, 2024
HealthCRED secures US$ 1.2 million in seed funding
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Subscribe To Our Newsletter & Stay Updated
